TOP > 外国特許検索 > CANCER VACCINE

CANCER VACCINE

外国特許コード F120006485
整理番号 S2010-0447-C0
掲載日 2012年5月7日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2011JP057777
国際公開番号 WO 2011122611
国際出願日 平成23年3月29日(2011.3.29)
国際公開日 平成23年10月6日(2011.10.6)
優先権データ
  • 特願2010-078625 (2010.3.30) JP
発明の名称 (英語) CANCER VACCINE
発明の概要(英語) A cancer vaccine which can be used for the prevention and treatment of cancer. Disclosed are: a peptide which can efficiently induce an immune response to cancer and which comprises SEQ ID No. 1 (KMHIRSHTL) or SEQ ID No. 2 (RTFSRMSLL); an antigen presenting cell which displays the peptide on the cell surface thereof; a T cell which is induced by the antigen presenting cell; a cancer vaccine which contains the peptide, an expression vector which expresses said peptide, and an antigen presenting cell which displays the peptide or a T cell which is induced by the antigen presenting cell. Further disclosed is a cancer treatment and prevention method using the cancer vaccine.
従来技術、競合技術の概要(英語) BACKGROUND ART
In recent years, in cancer immunology, cancer antigens recognized by immune cells has been elucidated that the mechanism is significant. According to this method, first, an antigen presenting cell is dendritic cells (dendritic cells or DC), within the cell, the protein expressed by a cancer is generated when decomposing the antigenic peptide 8-10 amino acids, or major histocompatibility antigen complex (major histocompatibility complex MHC; in humans, human leukocyte antigen or HLA) to and presented on the cell surface. Cytotoxic T cells (cytotoxic T lymphocyte or CTL) is, a dendritic cell surface of class I HLA and an antigen conjugated to the peptides can be recognized, activation, growth, and invade into the tumor, cancer cells with the protein derived from the antigenic peptides the cells against injury (for example, 126 Arch.Surg. (1990): 200-205 reference).
Using this mechanism, a method for treating cancer have been developed as a cancer vaccine. For example, an antigenic peptide derived from a cancer - specific protein presented on the cell surface of dendritic cells produced in vitro, grown, or administered to cancer patients, that was trained by the dendritic cells to administer cytotoxic T cells by, cancer in the patient's body to induce cancer immunity. Or, a cancer - specific protein administered to a cancer patient, the patient's body, throughout the course of the cancer to induce immune mechanisms in (for example, Science (1991) 254:1643-1647, J.Exp.Med. (1996) 183:1185-1192, J. Immunol. (1999) 163:4994-5004, Proc.Natl.Acad.Sci.USA (1995) 92: 432-436, Science (1995) 269:1281-1284, 186 J.Exp.Med. (1997): 785-793 reference).
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • KEIO UNIVERSITY
  • 発明者(英語)
  • KUDO, Chie
  • KAWAKAMI, Yutaka
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IS KE KG KM KN KP KR KZ LA LC LK LR LS LT LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PE PG PH PL PT RO RS RU SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ MD RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
ライセンスをご希望の方、特許の内容に興味を持たれた方は、下記問合せ先にご相談下さい。

PAGE TOP

close
close
close
close
close
close